Protagonist Therapeutics
PTGX
PTGX
136 hedge funds and large institutions have $522M invested in Protagonist Therapeutics in 2022 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 51 increasing their positions, 42 reducing their positions, and 15 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
5% more funds holding
Funds holding: 129 → 136 (+7)
3.18% more ownership
Funds ownership: 96.17% → 99.36% (+3.2%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Holders
136
Holding in Top 10
1
Calls
$10.4M
Puts
$2.59M
Top Buyers
| 1 | +$16.2M | |
| 2 | +$12.5M | |
| 3 | +$9.51M | |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$6.98M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$5.59M |
Top Sellers
| 1 | -$29.9M | |
| 2 | -$24.2M | |
| 3 | -$9.64M | |
| 4 |
RI
RTW Investments
New York
|
-$6.38M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
-$2.83M |